UK Markets open in 6 hrs 17 mins

Trillium Therapeutics Inc. (0VLS.L)

LSE - LSE Delayed price. Currency in CAD
Add to watchlist
13.72+5.56 (+68.14%)
At close: 6:31PM GMT
Full screen
Previous close8.16
Open13.67
Bid0.00 x N/A
Ask0.00 x N/A
Day's range13.67 - 13.72
52-week range13.67 - 13.72
Volume300
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)1.89
PE ratio (TTM)N/A
EPS (TTM)-0.88
Earnings date13 May 2021 - 17 May 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • How Many Trillium Therapeutics Inc. (TSE:TRIL) Shares Do Institutions Own?
    Simply Wall St.

    How Many Trillium Therapeutics Inc. (TSE:TRIL) Shares Do Institutions Own?

    The big shareholder groups in Trillium Therapeutics Inc. ( TSE:TRIL ) have power over the company. Insiders often own a...

  • These 3 Stocks Will Make You A Fortune If They Succeed
    Motley Fool

    These 3 Stocks Will Make You A Fortune If They Succeed

    Unfortunately, capturing that type of gain typically means investing while the company is still small and its outcome is uncertain. Trillium Therapeutics (NASDAQ: TRIL), Vaxart (NASDAQ: VXRT), and Twist Biosciences (NASDAQ: TWST) have ambitions so big, they could produce these life-changing returns from the big-risk, big-reward portion of a diversified portfolio. Jan Skvarka, who Trillium introduced as CEO near the end of 2019, has said the company's long-term goal is to challenge chemotherapy.

  • 3 Top Biotech Stocks for Spring 2021
    Motley Fool

    3 Top Biotech Stocks for Spring 2021

    What do playing right field in baseball, deep-sea fishing, and investing in small biotech stocks have in common? For shareholders of bluebird bio (NASDAQ: BLUE), Sage Therapeutics (NASDAQ: SAGE), and Trillium Therapeutics (NASDAQ: TRIL), spring announcements may pierce the monotony with updates on key drug development programs. After those stocks' recent struggles, management teams and shareholders are hoping the news will get their share prices moving back toward previous highs.